Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Ionis Pharmaceuticals

Tracked across 11 events · 176 articles · First seen Apr 20, 2026 · Last active Sep 24, 2026

Sentiment
16
Attention
6
Events
11
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 75
Business
Impact: Ionis Pharmaceuticals entered into a license agreement with Recordati for zilganersen outside the U.S., retaining U.S. commercial rights and receiving an upfront payment of $30 million, milestone payments, and royalties. This deal strengthens its position in neurology and rare diseases.
Jun 25, 2026 · 6 articles
3 -60
Business
Impact: Ionis's stock plunged 23.9%, losing over $3.3 billion in market cap; it is the primary target of multiple securities investigations.
Jul 09, 2026 · 46 articles
4 45
Tech
F. Hoffmann-La Roche — Genentech, a member of the Roche Group, and its partner Ionis Pharmaceuticals announced positive prespecified interim results from the ongoing Phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary…
Impact: Ionis licensed sefaxersen to Roche and stands to gain milestone and royalty revenue if the Phase III program succeeds, validating its antisense platform.
Sep 23, 2026 · 6 articles
6 70
Tech
Impact: Ionis Pharmaceuticals co-developed bepirovirsen, and the positive trial results and potential approval could lead to substantial financial gains and increased market presence for the company.
May 28, 2026 · 8 articles
6 55
Tech
Impact: Ionis partnered with Biogen on diranersen, an antisense oligonucleotide. Positive trial results enhance Ionis's platform value and pipeline prospects.
Jul 14, 2026 · 22 articles
4 -40
Business
Impact: Ionis will not receive milestone payments from Royalty Pharma and loses potential pelacarsen royalties, though Spinraza royalties continue.
Sep 04, 2026 · 12 articles
6 -30
Regulatory
Impact: Ionis Pharmaceuticals, a mid-sized drugmaker, expressed disinterest in the United States — Medicaid pilot program due to its business model and limited upside, highlighting the challenges in getting smaller companies to participate.
Apr 20, 2026 · 6 articles
6 50
Tech
Impact: Ionis Pharmaceuticals discovered diranersen and licensed it to Biogen in 2019, making it a beneficiary of any future success of the drug.
May 14, 2026 · 7 articles
4 -10
Business
Impact: Ionis Pharmaceuticals is the partner for Wainua, which failed in a heart disease trial earlier this year, contributing to the series of setbacks for AstraZeneca.
Aug 17, 2026 · 20 articles
6 20
Domestic
On August 31, 2026, President Donald Trump announced voluntary drug pricing agreements with nine pharmaceutical companies: Alcon, Astellas Pharma, BeOne Medicines, BridgeBio Pharma, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. These companies agreed…
Impact: Ionis Pharmaceuticals was mentioned as a smaller drugmaker that saw little financial benefit in joining the MFN program, highlighting industry hesitation.
Aug 18, 2026 · 37 articles
3 0
Business
Impact: Ionis Pharmaceuticals is mentioned as the former company of n-Lorem's founder, but is not directly involved in this collaboration.
Jul 27, 2026 · 6 articles
AstraZeneca ↔ Ionis Pharmaceuticals
AstraZeneca ↔ Ionis Pharmaceuticals
ERGEN INTELLIGENCE
Track Ionis Pharmaceuticals live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.